Aurobindo Pharma received FDA approval for its generic Risedronate Sodium oral tablets, opening a new revenue opportunity within the osteoporosis market. This clearance allows the manufacturer to enter the established bisphosphonate sector and capitalize on growing demand for bone health treatments.